Methods for treating ulcerative colitis
Patent 5707622 Issued on January 13, 1998. Estimated Expiration Date: 
March 1, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 1, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesRecombinant immunoglobin preparations Patent #: 4816567 InventorsApplicationNo. 396851 filed on 03/01/1995US Classes:424/145.1, Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tPA, etc.), or fibrin424/133.1, Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)424/141.1, Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology)424/158.1, Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, vascular permeability factor, etc.); or binds serum protein, plasma protein, fibrin, or enzyme530/387.3, Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)530/388.1, Monoclonal530/388.23Binds lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.)ExaminersPrimary: Loring, Susan A.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 039/395C07K 016/00 C07K 016/18 C07K 016/24 AbstractAnti-IL-8 monoclonal antibodies are described for use in diagnostic applications and in the treatment of inflammatory disorders such as inflammatory bowel disease and bacteria pneumonias.Other References
Field of SearchBinds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, vascular permeability factor, etc.); or binds serum protein, plasma protein, fibrin, or enzymeStructurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.) Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tPA, etc.), or fibrin Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology) Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.) Binds lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.) Monoclonal |
| ||||||||||||||
